HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Products In Brief: Salonpas gel, algal protein in CleanSeries, Kemin eye health line, Merck supplies Solgar folate

This article was originally published in The Tan Sheet

Executive Summary

Salonpas gel targets pain precisely; Twinlab adds algal protein to CleanSeries; ZeaONE expands Kemin eye health line; Merck supplies Solgar folate; Cyvex offers fish-derived protein powder; NeuroScience calming products now dissolvable; Organix-South soothes with neem rub.

You may also be interested in...



In Brief

FDA approves OTC HIV test; Good Herbs disclaimer does not cancel drug claims; American Herbal Pharmacopoeia releases blue cohosh monograph; salmonella triggers Standard Process supplement recall; Kemin, Ball see zeaxanthin partnership bloom; more In Brief.

US Interim Funding Bill Gets Biden’s Signature; Window Narrows For Cosmetics, Dietary Supplement Legislation

Passed by the US House and signed into law on 30 September, the Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023, avoids a partial government shutdown and furloughs in FDA user-fee programs. Policy riders stripped from the legislation, including for cosmetics and dietary supplement regulatory changes, could still find their way into a final FY 2023 spending omnibus.

US Interim Funding Bill Gets President Biden’s Signature; Window Narrows For IVD Reg Reform

Passed by the US House and signed into law on 30 September, the Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023, avoids a partial government shutdown and furloughs in FDA user-fee programs including MDUFA. Policy riders stripped from the legislation, including for FDA oversight of lab-developed tests, could still find their way into a final FY 2023 spending omnibus.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS124130

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel